- Following $1.25 million donation, UC Berkeley launching Center for the Science of Psychedelics
- Pure Extract Technologies Inc. expanding into functional and medicinal mushroom market
- Psychedelic compounds increasingly being studied to treat wide range of physical, mental conditions
- Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell, functional mushroom products
For hundreds of years, medicinal mushrooms have been revered among both ancient and modern cultures throughout the world for their nutritional and medicinal qualities. Pure Extract Technologies, a private plant-based Canadian extraction company headquartered in British Columbia, is leveraging the latest in science in its goal to become the leading extraction company engaged in the development and commercialization of functional and medicinal products.
Psychedelics appear to be going mainstream, as evidenced by the planned launch of the UC Berkeley Center for the Science of Psychedelics following an anonymous donation of $1.25 million for startup costs. Last studied over 50 years ago, UC Berkeley is once again opening the doors to psychedelic research with an aim to study the possible medical benefits of psychedelic drugs, specifically the chemical compound psilocybin found in “magic” mushrooms.
“There’s never been a better time to start a center like this,” said UC Berkeley neuroscientist and co-founder David Presti. “The renewal of basic and clinical science with psychedelics has catalyzed interest among many people.”
Psychedelic compounds are increasingly being researched for possible benefits that include anti-tumor effects, improved immune function, anti-viral properties, mental wellness benefits and detoxification. Specific neurochemical-related conditions of particular interest to leading academic and medical research institutions include depression, anxiety, PTSD, obesity, narcolepsy, bipolar disorder, Alzheimer’s, OCD, ADHD and drug and alcohol addiction.
Psychedelics were granted FDA breakthrough therapy status for treatment-resistant depression in 2020 with approvals expected in 2021.
Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell and produce functional mushroom products in an EU-GMP-compliant environment, adequately positioning the Company to partner with organizations that plan to develop both functional and psychedelic products. Further solidifying the Company’s position on a global scale is its 10,000 square foot facility designed for EU-GMP certification that will enable sales throughout the world.
In addition to functional and medicinal products, Pure Extracts’ business model consists of three other verticals in connection with its existing cannabis and hemp extraction business. They include the marketing of in-house brands; toll processing – services in connection with the conversion of raw biomass into extracted oil products; and white labeling – the supply of products to existing brands looking to sell edibles, custom formulated oils and other cannabis-related products.
With a top spot among the fastest growing industries in North America, the mushroom industry is currently in a transitory phase whereby dry biomass is being converted to extracts. With a strong position in the industry, Pure Extracts is poised to benefit from this emerging trend as mushroom based products continue to enter mainstream awareness, bolstered by scientific research and ages-old therapeutic use.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.